912773-22-9

Basic information

• Product Name: 6-Bromo-pyrazolo[1,5-a]py...
• Synonyms: 6-Bromo-pyrazolo[1,5-a]py...;6-bromopyrazolo[1,5-a]pyrimidine-3-carboxylic acid(SALTDATA: FREE)
• CAS NO: 912773-22-9
• Molecular Formula: C₇H₄BrN₃O₂
• Molecular Weight: 242.02956
• Mol File: 912773-22-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 2.09±0.1 g/cm3(Predicted)
• PKA: -0.21±0.41(Predicted)
• CAS DataBase Reference: 6-Bromo-pyrazolo[1,5-a]py...(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-pyrazolo[1,5-a]py...(912773-22-9)
• EPA Substance Registry System: 6-Bromo-pyrazolo[1,5-a]py...(912773-22-9)

Safety Data

• Hazardous Substances Data: 912773-22-9(Hazardous Substances Data)

Usage

General Description

6-Bromo-pyrazolo[1,5-a]pyridine-3-carbonitrile is a chemical compound with the molecular formula C7H3BrN4. It is a pyrazolopyridine derivative that is commonly used in the pharmaceutical industry as a building block for the synthesis of various biologically active compounds. 6-Bromo-pyrazolo[1,5-a]py... has shown potential as a kinase inhibitor, making it an important tool for drug discovery and development. Additionally, its unique structure and properties have made it a valuable reagent in the field of organic chemistry, where it is used for the development of novel synthetic methods and strategies. Overall, 6-Bromo-pyrazolo[1,5-a]pyridine-3-carbonitrile is a versatile compound with important applications in both the chemical and pharmaceutical industries.

InChI:InChI=1S/C7H4BrN3O2/c8-4-1-9-6-5(7(12)13)2-10-11(6)3-4/h1-3H,(H,12,13)

Upstream product

• 2065-75-0 2-Bromo-malonaldehyde 
• 41680-34-6 3-aminopyrazole-4-carboxylic acid 
• 41680-34-6 5-amino-1H-pyrazole-4-carboxylic acid 

Downstream Products

• 1204925-71-2 6-bromo-3-[((2S)-2-methyl-4-{[4-(trifluoromethyl)phenyl]sulfonyl}-1-piperazinyl)carbonyl]pyrazolo[1,5-a]pyrimidine 
• 1065080-92-3 N-(2-amino-2-oxoethyl)-6-{[3-(trifluoromethyl)phenyl]thio}pyrazolo[1,5-a]-pyrimidine-3-carboxamide 

Relevant articles and documents

Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders

Herein, we describe the discovery of a potent, selective, brain-penetrating, in vivo active phosphodiesterase (PDE) 2A inhibitor lead series. To identify high-quality leads suitable for optimization and enable validation of the physiological function of PDE2A in vivo, structural modifications of the high-throughput screening hit 18 were performed. Our lead generation efforts revealed three key potency-enhancing functionalities with minimal increases in molecular weight (MW) and no change in topological polar surface area (TPSA). Combining these structural elements led to the identification of 6-methyl-N-((1R)-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (38a), a molecule with the desired balance of preclinical properties. Further characterization by cocrystal structure analysis of 38a bound to PDE2A uncovered a unique binding mode and provided insights into its observed potency and PDE selectivity. Compound 38a significantly elevated 3′,5′-cyclic guanosine monophosphate (cGMP) levels in mouse brain following oral administration, thus validating this compound as a useful pharmacological tool and an attractive lead for future optimization.

HETEROCYCLIC COMPOUND

A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.